Morepen Labs starts test production of Sputnik V at Himachal facility

The first batch will be shipped to Gamaleya Center for quality control. RDIF and Morepen Laboratories have signed a cooperation agreement in June 2021 and are actively implementing the technology transfer, it added.

"As the pandemic is yet far from over and new, more dangerous variants of coronavirus are being detected in various regions of the world, RDIF is increasing capacities for the production of Sputnik V in India, one of the key hubs," RDIF CEO Kirill Dmitriev said.

Agreement with Morepen Laboratories provides for larger amounts of Sputnik V to be available, "both for India and our partners globally to speed up the vaccination with one of the best vaccines in the world," he added.

RDIF has already reached agreements earlier with other pharmaceutical companies - Gland Pharma, Hetero Biopharma, Panacea Biotec, Stelis Biopharma and Virchow Biotech - in India for the vaccine.

In total, agreements with partners in India provide for the production of more than 850 million doses of Sputnik V per year, the statement said.

Read also: Morepen Labs net profit leaps over 6 fold to Rs 27crore in Q2

"We are delighted to partner with RDIF for the prestigious project of Sputnik V production in India," Morepen Laboratories Chairman and MD Sushil Suri said.

Sputnik V is based on a proven and well-studied platform of human adenoviral vectors and uses two different vectors for the two shots in a course of vaccination, the statement said.